Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Components of survival time of screen detected cancer cases

Principal Investigator
Name
Philip Prorok
Institution
NCI
Position Title
Scientific Program Manager
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-117
Initial CDAS Request Approval
Feb 3, 2015
Title
Components of survival time of screen detected cancer cases
Summary
The goal of this project is to estimate the mean duration of the components of the survival time of individuals who are diagnosed with screen detected cancer. The fact that the numbers of cases in the arms of a randomized screening trial are equal on average in the absence of screening is exploited. Using mean lead time from standard approaches and the number of cases in each arm yields the mean preclinical duration and the mean benefit time. Four settings are considered – benefit yes, no and overdiagnosis yes, no. Data to address these four settings are requested from the following trials: NLST, PLCO-O, PLCO-L, HIP, and Mayo Clinic. Required data elements include identifier, cohort (screened, refused, control), times from entry to diagnosis, entry to death, and diagnosis to death, mode of detection, and cause of death.
Aims

Estimation of the preclinical sojourn time and benefit time of screen detected cancer cases both with and without overdiagnosis.

Collaborators

Karen Kafadar - University of Virginia
Maria Ferrarra - University of Virginia